Orally Inhaled Flecainide for Conversion of Atrial Fibrillation to Sinus Rhythm: INSTANT Phase 2 Trial.

Abstract

INSTANT (INhalation of flecainide to convert recent-onset SympTomatic Atrial fibrillatioN to sinus rhyThm) was a multicenter, open-label, single-arm study of flecainide acetate oral inhalation solution (FlecIH) for acute conversion of recent-onset (≤48 hours) symptomatic atrial fibrillation (AF) to sinus rhythm. This study investigated the efficacy and safety in 98 patients receiving a single dose of FlecIH delivered via oral inhalation. Patients self-administered FlecIH over 8minutes in a supervised medical setting using a breath-actuated nebulizer and were continuously monitored for 90minutes using a 12-lead Holter. Mean age was 60.5 years, mean body mass index was 27.0kg/m2, and 34.7% of the patients were women. All patients had≥1 AF-related symptoms at baseline, and 87.8% had AF symptoms for≤24 hours. The conversion rate was 42.6% (95%CI: 33.0%-52.6%) with a median time to conversion of 14.6minutes. The conversion rate was 46.9% (95%CI: 36.4%-57.7%) in a subpopulation that excluded predose flecainide exposure for the current AF episode. Median time to discharge among patients who converted was 2.5 hours, and only 2 patients had experienced AF recurrence by day 5. In the conversion-no group, 44 (81.5%) patients underwent electrical cardioversion by day 5. The most common adverse events were related to oral inhalation of flecainide (eg, cough, oropharyngeal irritation/pain), which were mostly of mild intensity and limited duration. The risk-benefit of orally inhaled FlecIH for acute cardioversion of recent-onset AF appears favorable. FlecIH could provide a safe, effective, and convenient first-line therapeutic option. (INhalation of Flecainide to Convert Recent Onset SympTomatic Atrial Fibrillation to siNus rhyThm [INSTANT]; NCT03539302).